AP
SRNE

AlpInvest Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

AlpInvest Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-86,540
Closed -$726K – 36
2015
Q3 		$726K Buy
+86,540
New +$1.38M 1.43% 20

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AlpInvest Partners's SRNE Position: Q4 2015 in Review

AlpInvest Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2015, closing a stake of 86,540 shares — an estimated $726K sold.

AlpInvest Partners first reported a position in SRNE in Q3 2015 and held it in 1 quarter. The position peaked at $726K in Q3 2015. 84 funds tracked by Wall St. Rank hold SRNE as of Q4 2015.

  • AlpInvest Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • AlpInvest Partners sold 86,540 Sorrento Therapeutics, Inc. shares in Q4 2015, an estimated $726K.
  • AlpInvest Partners first reported a position in Sorrento Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • AlpInvest Partners's Sorrento Therapeutics, Inc. position peaked at $726K in Q3 2015.
  • 84 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2015.

Based on AlpInvest Partners's 13F filing for Q4 2015, filed 12 Feb 2016.